TY - JOUR

T1 - Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline

T2 - A post hoc subgroup analysis

AU - Kushner, Robert F.

AU - Fink-Jensen, Anders

AU - Frenkel, Ofir

AU - McGowan, Barbara

AU - Goldman, Bryan

AU - Overvad, Maria

AU - Wadden, Thomas

N1 - Publisher Copyright: © 2023 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.

PY - 2024

Y1 - 2024

N2 - Objective: To explore the efficacy and safety of semaglutide 2.4 mg in people with overweight/obesity who were also being treated with antidepressants (ADs). Methods: Across the Semaglutide Treatment Effect for People with obesity (STEP) 1–3 and 5 trials, adults with overweight/obesity and type 2 diabetes (STEP 2 only) were enrolled. People with severe major depressive disorder within 2 years prior to screening or with a patient health questionnaire-9 score ≥15 at screening were excluded. Participants were categorized into subgroups according to baseline AD status (on/off ADs) in this post hoc exploratory analysis of the STEP trials. Results: Of 3683 participants randomized, 539 were on ADs at baseline. Mean body weight change from baseline to week 68 was greater for semaglutide versus placebo, regardless of baseline AD use. In STEP 1, for participants on ADs at baseline, mean change from baseline was −15.7% with semaglutide versus −0.2% with placebo and −14.7% versus −2.8% for those not on ADs at baseline. Similar patterns were seen in STEP 2, 3, and 5. The prevalence of adverse events (AEs) was generally similar between semaglutide and placebo in participants on ADs at baseline. Conclusions: In adults with overweight/obesity, semaglutide provided clinically meaningful weight loss regardless of baseline AD use, with an AE profile consistent with previous studies.

AB - Objective: To explore the efficacy and safety of semaglutide 2.4 mg in people with overweight/obesity who were also being treated with antidepressants (ADs). Methods: Across the Semaglutide Treatment Effect for People with obesity (STEP) 1–3 and 5 trials, adults with overweight/obesity and type 2 diabetes (STEP 2 only) were enrolled. People with severe major depressive disorder within 2 years prior to screening or with a patient health questionnaire-9 score ≥15 at screening were excluded. Participants were categorized into subgroups according to baseline AD status (on/off ADs) in this post hoc exploratory analysis of the STEP trials. Results: Of 3683 participants randomized, 539 were on ADs at baseline. Mean body weight change from baseline to week 68 was greater for semaglutide versus placebo, regardless of baseline AD use. In STEP 1, for participants on ADs at baseline, mean change from baseline was −15.7% with semaglutide versus −0.2% with placebo and −14.7% versus −2.8% for those not on ADs at baseline. Similar patterns were seen in STEP 2, 3, and 5. The prevalence of adverse events (AEs) was generally similar between semaglutide and placebo in participants on ADs at baseline. Conclusions: In adults with overweight/obesity, semaglutide provided clinically meaningful weight loss regardless of baseline AD use, with an AE profile consistent with previous studies.

U2 - 10.1002/oby.23946

DO - 10.1002/oby.23946

M3 - Journal article

C2 - 37989717

AN - SCOPUS:85177446504

VL - 32

SP - 273

EP - 280

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 2

ER -